Leuprolide acetate and central retinal vein occlusion.
A 63-year-old man suffered a central retinal vein occlusion 2 months after he began taking leuprolide acetate for prostate cancer. Despite control for possible systemic hypertension (126/90 mm Hg) and mild hypercholesterolemia (total cholesterol level =246 mg/dL [range: 16 to 200 mg/dL], high-density lipoprotein level =67 mg/dL [range: 40 to 59 mg/dL], and low-density lipoprotein level =144 mg/dL [range: 0 to 130 mg/dL]), progression of the venous occlusive disease occurred. Leuprolide acetate, which is associated with thromboembolic events and diffuse intravascular coagulation, may be implicated in central retinal vein occlusion.
Federici
Thomas J
TJ
Department of Ophthalmology, University of South Carolina, 4 Medical Park, Suite 300, Columbia, SC 29203, USA. tfederici@gmail.com
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D005451:Fluorescein Angiography; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012170:Retinal Vein Occlusion / Q000139:chemically induced* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide